abstract BACKGROUND: Acute otorrhea is a common problem in children with tympanostomy tubes. We recently demonstrated that treatment with antibiotic-glucocorticoid eardrops is clinically superior to oral antibiotics and initial observation. The aim of this study was to assess the cost-effectiveness of these three common treatment strategies for this condition.
WHAT'S KNOWN ON THIS SUBJECT:
Otorrhea is common in children with tympanostomy tubes: annually, 2 of 3 children develop 1 or more episodes. Antibiotic-glucocorticoid eardrops are the most effective treatment in both the shortand long-term.
WHAT THIS STUDY ADDS:
Treatment with antibiotic-glucocorticoid eardrops costs less than oral antibiotics and initial observation in children with tympanostomy tubes who develop otorrhea. Non-health care costs constitute a substantial proportion of the total costs of this condition.
With ∼50 000 procedures in the Netherlands, .20 000 in the United Kingdom, and almost 700 000 in the United States each year, insertion of tympanostomy tubes (also known as grommets or ventilation tubes) is one of the most frequently performed surgical procedures in children (Dutch Hospital Database [Landelijke medische registratie], 2010). [1] [2] Annually, 2 of 3 children with tympanostomy tubes develop 1 or more episodes of otorrhea: this is caused by an acute middle ear infection, whereby middle ear fluid drains through the tube. 3 As parents generally hope that tympanostomy tubes will solve their child's middle ear problems, they may be disappointed, or anxious, when their child develops otorrhea.
The societal costs of middle ear infections are considerable. [4] [5] [6] Previously, Roland et al 7 showed, by using decision-analytic modeling, that the direct health care costs of a single episode of otorrhea in children with tubes approximated US $250 in 2004. In addition, parents often have to stay home from work when their child is unable to go to day care or school, leading to high non-health care costs. [8] [9] [10] We recently demonstrated that topical treatment with antibioticglucocorticoid eardrops is more effective than oral antibiotics and initial observation in children with tube discharge. 11 The objective of this article was to establish for the first time the cost-effectiveness of these treatment strategies.
METHODS

Design and Participants
This cost-effectiveness study was performed alongside an open-label pragmatic randomized trial in the Netherlands. Its design, methods, and clinical outcomes are reported in more detail elsewhere. 11 The study was approved by the medical ethics committee of the University Medical Centre Utrecht and was monitored according to the Good Clinical Practice quality standard.
Family physicians and ear, nose, and throat (ENT) surgeons approached parents of children with tympanostomy tubes for trial participation. Parents interested in trial participation contacted our research team when their child developed otorrhea. Children aged between 1 and 10 years with discharge for up to 7 days were eligible for trial participation. We excluded children with a body temperature .38.5°C, those who had used antibiotics in the previous 14 days, those who had tubes inserted within the previous 14 days, and those who had experienced another episode of otorrhea in the previous 28 days, had $3 episodes of otorrhea in the previous 6 months, or had $4 episodes in the previous year. We also excluded children with Down syndrome, craniofacial anomalies, a known immunodeficiency, and children with a known allergy to the medications used in this study.
Randomization and Interventions
After obtaining informed consent, children were randomized to 1 of 3 treatment strategies: hydrocortisonebacitracin-colistin eardrops (5 drops, 3 times daily in the discharging ear[s] for 7 days), oral amoxicillinclavulanate suspension (30 mg amoxicillin and 7.5 mg clavulanate per kilogram of body weight per day, divided into 3 daily doses taken orally for 7 days), or initial observation for 14 days. After the first follow-up visit, further management of otorrhea was left to the discretion of the child's family physician or ENT surgeon.
Follow-up Measurements
Parents kept a daily diary capturing ear-related symptoms, direct health care resource use (prescriptions, health care visits, surgical procedures, and hospitalizations) and direct (over-the-counter drugs, travel costs, costs for child care) and indirect non-health care costs (parental time of work) for 6 months. We used monthly telephone reminders to optimize compliance with completing the daily diary.
At 2 weeks and 6 months, the study doctor visited the children at home, performed otoscopy, and checked diaries for completeness. Data quality was monitored by an independent third party, including close-in and close-out visits and regular on-site visits for source data verification.
Clinical Outcomes
Clinical effectiveness of antibioticglucocorticoid eardrops, oral antibiotics, and initial observation was assessed by the following:
1. otoscopy by the study doctor at 2 weeks (ie, treatment failure defined as presence of otorrhea); and 2. parental diaries at 6 months (ie, mean number of days with otorrhea). Parental time off work was calculated per hour, averaging hourly production losses for men and women, assuming parents to be between 25 and 35 years of age. Hourly estimates were derived from the Dutch guideline for pharmacoeconomic evaluation and are corrected for the elasticity of labor productivity. 13 The hourly cost estimate for child care was derived from the Dutch National Institute for Family Finance Information (NIBUD). 16 Travel expenses were calculated for health care visits, surgical procedures, and hospitalizations following the Dutch guideline for pharmacoeconomic evaluation. 13 The most relevant cost estimates are given in Table 1 ; a comprehensive overview can be found in Supplemental Table 5 .
Resource Use and Valuation
Statistical Analysis
We used a short time horizon for all analyses and therefore took no discount rate into account. First, we compared the clinical effectiveness of the treatment strategies by the following:
1. calculating the risk differences (RD), with 95% confidence intervals (CI) and numbers needed to treat (NNT), for treatment failure, defined as otoscopic presence of otorrhea at 2 weeks (short-term clinical outcome); and 2. calculating the differences in mean number of days with otorrhea during 6 months of follow-up, with 95% CIs (long-term clinical outcome).
Second, by using a societal perspective, we compared the costs within the 3 treatment groups by calculating mean costs per patient, a Assessed by doctor. b Short-term diary of 1 child was missing for whom we did have a primary outcome assessment (this child was excluded), so results are slightly different from our previous publication. 11 c As reported in parental diary.
with SEs, in both the short (2 weeks) and long term (6 months).
Third, we compared differences in costs between groups to differences in clinical effects between groups, by calculating incremental costeffectiveness ratios. Short-term costeffectiveness was expressed as the costs to treat the number of patients needed to prevent 1 treatment failure at 2 weeks. Long-term costeffectiveness was expressed as cost per day with otorrhea avoided at 6 months of follow-up. 
Completeness of Data
At 2 weeks, clinical outcomes and parental diaries, including resource use data were available for 227 (99%) of the 230 children ( Supplemental Fig 2) . At 6 months, 221 (96%) parental diaries were available.
Clinical Outcomes
Antibiotic-glucocorticoid eardrops were superior to oral antibiotics and initial observation both at 2 weeks and 6 months ( Table 2) . At 2 weeks, 5% of children treated with eardrops had otorrhea versus 44% of those treated with oral antibiotics (RD -39%, 95% CI -51% to -26%, NNT 3) and 55% of those allocated to initial observation (RD -49%, 95% CI -62% to -37%, NNT 2). At 6 months, the mean number of days with otorrhea was 10 in children treated with eardrops versus 16 in those treated with oral antibiotics (mean difference -6.5, 95% CI -10.4 to -2.6) and 24 in those allocated to initial observation (mean difference -14.2, 95% CI -20.4 to -8.1).
Costs
Mean costs per patient were lower in children treated with antibioticglucocorticoid eardrops than in those receiving oral antibiotics or initial observation in both the short and long term (Tables 3 and 4) . At 2 weeks, the mean total costs per patient were US $42.43 (SE 4.92) for 
Balancing Effects and Costs
Treatment with antibioticglucocorticoid eardrops is both clinically superior and has economic benefits over oral antibiotics and initial observation. Because of this dominance, calculating incremental cost-effectiveness ratios is redundant.
The cost-effectiveness plane resulting from the probabilistic sensitivity analyses over 6 months show eardrops to be superior in terms of clinical effectiveness in 100% of the bootstrap samples, with lower costs as compared with oral antibiotics and initial observation in 71% and 99% of the bootstrap samples, respectively (Fig 1) .
DISCUSSION
Antibiotic-glucocorticoid eardrops are clinically superior and cost less than oral antibiotics and initial observation in children with tympanostomy tubes who develop otorrhea. Non-health care costs constitute a substantial proportion of the total costs of this condition.
We are the first to present costeffectiveness of the most common treatment strategies in children with tubes and otorrhea. This economic evaluation was conducted alongside a pragmatic randomized trial, which is considered the best approach for economic evaluations. 17 Adherence to the allocated treatment strategies in the first 2 weeks was high and we were able to include almost all (99% of randomized children in the short term and 97% in the long term) of included children in the costeffectiveness analysis.
Some aspects of our study deserve further attention. First, we used a pragmatic, nonblinded trial design to enhance the applicability of our findings to daily practice. Observer and reporting bias were reduced by using 2 different clinical and objective outcomes, 1 reported by a physician and 1 reported by parents, which were consistent in favoring eardrops, while strictly adhering to our predefined outcomes and statistical analyses plan as listed in our study protocol. 11 Second, hydrocortisonebacitracin-colistin eardrops are not routinely available in most countries. We believe that the clinical effectiveness of any combination of antibiotic-glucocorticoid eardrops with a similar antimicrobial activity profile will be the same. 11 Third, the health care costs of all 3 treatment strategies may be somewhat higher than we have reported because we did not include data on diagnostic procedures (eg, sampling for microbiological analysis, audiometry) during follow-up. Because the number of diagnostic procedures will be related to persistence of symptoms, the true difference in costs between the groups may be even larger than reported. Fourth, the large SEs reflect the generally skewed distribution of costing data. Although one would use the median to present skewed clinical data, it is common to use the mean in cost-effectiveness analyses to assess the actual impact of interventions on health care budgets. The cost-effectiveness plane, based on bootstrapping techniques, provides a more reliable visualization of the sampling distribution. It shows that eardrops were more effective and less costly as compared with oral antibiotics and initial observation in the vast majority of the samples. Fifth, we chose to balance the societal costs with clinical outcomes instead of quality-adjusted life years. When our trial started, no suitable questionnaire was available for children to self-report their generic health-related quality of life. The most commonly used instrument in economic evaluations, the EQ5D (Youth) requires collection by proxy in children (,8 years of age) and
FIGURE 1
Cost-effectiveness plane, showing incremental costs (in US Dollars) and effects of antibioticglucocorticoid eardrops as compared with oral antibiotics (blue 1) and initial observation (red 3) during 6 months of follow-up, with percentages of bootstrap samples per quadrant.
therefore does not provide direct health-related quality of life outcomes, but observational assessment of a child's functioning. [18] [19] [20] In our trial, as previously reported, the generic and disease-specific health-related quality-of-life scores at baseline indicated good quality of life and were similar across the groups. 11 The change in generic health-related quality-of-life scores at 2 weeks of follow-up did not differ significantly among the study groups. The changes in disease-specific health-related quality-of-life scores at 2 weeks were small but consistently favored eardrops. As such, we believe that use of health-related quality-of-life outcomes would not have changed our conclusions. Last, as recommended in economic evaluations, we included all health care resource use during follow-up in our analyses, although not all health care use may be directly related to the initial treatment strategies. Because the most expensive resources (ie, surgery and hospitalization) were higher in the children treated with eardrops than in those treated with oral antibiotics, and comparable to those allocated to initial observation, we believe that a different approach would not have altered our conclusions.
CONCLUSIONS
Antibiotic-glucocorticoid eardrops are clinically superior and cost less than oral antibiotics and initial observation in children with tympanostomy tubes who develop otorrhea, both in the short and long term.
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